Joining Canadian efforts for reducing colorectal cancer incidence and mortality
Colorectal cancer (CRC) is the second leading cause of cancer death among Canadians. CRC can be detected at early stages through colonoscopic surveillance and identifying those at increased risk is of utmost importance. The more advanced the disease at the time of diagnosis, the greater the risk of metastatic disease and resistance to treatment. The strong relationship between stage and prognosis, coupled with the response to novel and current therapies highlight the importance of integrating two major axes in the Canadian Colorectal Cancer Consortium (C4):
The C4 is looking for public and private organizations with the same mission of reducing the impact of CRC on the population using innovative research approaches to enhance screening and treatment outcomes.